Main Article Content

Kalman Filanovsky
Michal Haran
Vita Mirkin
Andrei Braester
Olga Shevetz
Anfisa Stanevsky
Erica Sigler
Ekaterina Votinov
Yehudit Zalzman-Amir
Alain Berrebi
Atan Gross
Lev Shvidel
(*) Corresponding Author:


Structural mitochondrial abnormalities as well as genetic aberrations in mitochondrial proteins have been known in Myelodysplastic syndrome (MDS) , yet there is currently little data regarding the metabolic properties and energy production of MDS cells. In the current study we used state-of-the-art methods to assess OXPHOS in peripheral blood cells obtained from MDS patients and healthy controls We then assessed the effect of food supplements- Coenzyme Q10 and carnitine on mitochondrial function and hematological response .We show here for the first time that in low risk MDS there is a significant impairment of mitochondrial respiration in peripheral blood cells and this can be improved with food supplements. We also show that such myelodysplastic syndrome, mitochondria, oxidative phosphorylation, coenzyme Q10, seahorse XF analyzer. supplements lead to improvement in cytopenia's and quality of life.

Downloads month by month


Download data is not yet available.

Article Details

Author Biography

Michal Haran, 1. Hematology Institute, Kaplan medical center, Rehovot, Israel; affiliated with the Hebrew university, Jerusalem, Israel

Author had equivalent role in manuscript preparation as first author


1. Maryanovich M, Oberkovitz G, Niv H, et al. The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells. Nat Cell Biol 2012;14:535–41.
2. Haran M, Gross A. Balancing glycolysis and mitochondrial OXPHOS: lessons from the hematopoietic system and exercising muscles. Mitochondrion 2014;19 Pt A3–7.
3. Cheson BD, GreenbergPl,BennettJM,Clinical application and proposal for modification of the International Working Group(IWG) response creteria in myelodisplasia.Blood 2006;108:419-5.
4. Sadighara M, Joktaji J.P, Hajhashemi V,et al. Protective effects of coenzyme Q10 and
L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats. Res Pharm Sci.2017;12:434-43.
5. Kulasekararaj AG, Mohamedali AM, Mufti GJ. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. British journal of haematology;162:587-605
6. Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-? in anemic patients with low-risk MDS. Leukemia 2018;32:2648–2658.
7.Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114:2393–2400.
8. Shlush LI. Change comes like a little wind: tales in MDS evolution. Blood 2016;128:1162–3
9. van de Loosdrecht AA, Brada SJ, Blom NR, et al. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. Leuk Res 2001;25:385–93.
10. Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res 2000;24:141–151.
11. Schildgen V, Wulfert M, Gattermann N. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. Exp Hematol 2011;39:666–75.e1.
12. Bowen D, Peddie C. Mitochondrial oxygen consumption and ineffective haematopoiesis in patients with myelodysplastic syndromes. Br J Haematol 2002;11:345–346.
13. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 2010;16:183–188.
14. Nicolson GL, Conklin ÆKA. Reversing mitochondrial dysfunction , fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp Metastasis 2008;161–169.
15. Galili N, Sechman E V, Cerny J, et al. Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10. Leuk Res 2007;31:19–26.
16. Liyanage SU, Hurren R, Voisin V, et al. Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. Blood 2017;129:2657–66.
17. Mohamedali AM, Alkhatabi H, Kulasekararaj A, et al. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood 2013;122:567–70.
18. Brandenburg NA, Yu R, Revicki DA. Reliability and Validity of the FACT-AN In Patients with Low or Int-1-Risk Myelodysplastic Syndromes with Deletion 5q. Blood;116:3827
19. an der Windt GJW, Chang C-H, Pearce EL. Measuring Bioenergetics in T Cells Using a Seahorse Extracellular Flux Analyzer. In: Current Protocols in Immunology. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2016. p3.16B.1-3.16B.14.